Cargando…
A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
In clinical trials, when exploring multiple dose groups to establish efficacy and safety on one or more selected doses, adaptive designs with interim dose selection are often used for dropping less effective dose groups. When it takes a long time to observe primary outcomes, utilizing information on...
Autores principales: | Chen, Xiaotian, Hartford, Alan, Zhao, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205753/ https://www.ncbi.nlm.nih.gov/pubmed/32395663 http://dx.doi.org/10.1016/j.conctc.2020.100562 |
Ejemplares similares
-
Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
por: Krendyukov, Andriy, et al.
Publicado: (2021) -
Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993) -
Using short-term endpoints to improve interim decision making and trial duration in two-stage phase II trials with nested binary endpoints
por: Zocholl, Dario, et al.
Publicado: (2023) -
The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005) -
Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)